A new study found that a Mediterranean-style diet may help slow the progression of prostate cancer in men who are not seeking immediate treatment. Men with localized prostate cancer who followed a more plant-based diet had a lower risk of cancer growth or advancement, regardless of their age, PSA levels, or tumor volume.
Researchers at University of Texas M. D. Anderson Cancer Center discovered NIK protein essential for T cell metabolic shift during activation, regulating anti-tumor immunity. Elevated NIK activity in T cells may improve adoptive therapy efficacy.
Researchers developed a gene expression signature that robustly predicts patient survival in patients with peritoneal carcinomatosis, a form of metastatic gastric cancer. The signature is associated with tumor cell populations and lineage compositions, offering potential for tailored treatment strategies.
The study showed that the combination of chemotherapy and blinatumomab resulted in increased survival rates and achieved a high rate of MRD negativity for patients with Ph-negative B-cell ALL. This treatment approach has the potential to improve long-term outcomes for these patients.
A novel targeted therapy, POMHEX, has been developed to block metabolic pathways in brain cancer cells with specific genetic defects. The study found that the small-molecule enolase inhibitor effectively killed brain cancer cells missing ENO1, and showed promise in animal models of this type of cancer.
Researchers from MD Anderson Cancer Center present promising clinical data on combination therapies for patients with metastatic melanoma and advanced refractory solid tumors. The treatments showed activity in activating immune pathways, leading to antitumor responses.
The study generated a valuable resource to aid in predicting drug sensitivity, understanding therapeutic resistance mechanisms, and identifying optimal combination treatment strategies. The dataset includes expression changes in over 200 clinically relevant proteins across more than 300 cell lines after treatment with 168 different com...
A Phase I trial found neoadjuvant combination immunotherapy with tremelimumab and durvalumab showed early signs of activity in patients with high-risk disease, with a pathologic complete response rate of 37.5%.
Researchers discovered that cancer mutations follow specific patterns, with internal factors leading to enriched mutations in active domains and external factors resulting in mutations in inactive domains. This understanding may lead to new therapeutic targets and treatment options.
A study at MD Anderson Cancer Center found that monitoring early changes in circulating tumor DNA can predict patient outcomes. Infused CAR T cells with certain characteristics are associated with better treatment responses, while those with exhaustion signatures may experience poor outcomes.
A new bioinformatics tool called DrBioRight has been developed to enable biomedical researchers to conduct routine analyses of large datasets without specialized expertise in bioinformatics or programming languages. The tool uses a natural-language interface to allow users to ask questions and receive intuitive analysis results.
In a Phase I clinical trial, sotorasib achieved a confirmed response rate of 32.2% and disease control rate of 88.1% in patients with KRAS G12C-mutant non-small cell lung cancer, with durable clinical benefits and manageable toxicities
A preclinical study from MD Anderson and BridgeBio's Navire Pharma shows that SHP2 inhibition can overcome osimertinib resistance in lung cancer. The study found that IACS-13909 suppressed tumor cell proliferation and caused tumor regression in various activated kinase-driven models.
A Phase II trial found that a combination of ipilimumab and nivolumab generated durable responses in 25% of patients with metastatic castration-resistant prostate cancer. The treatment achieved disease control in 46.9% of patients, with median progression-free survival of 5.5 months.
The Phase I/II LIBRETTO-001 trial found that selpercatinib achieved durable objective responses in the majority of participants with RET gene fusions, including an ORR of 85% in previously untreated patients. The study also showed promising results in patients with brain metastases and thyroid cancers.
A Phase II trial conducted at the University of Texas M. D. Anderson Cancer Center found a 51% overall response rate in patients with BRAF-mutated cholangiocarcinoma treated with dabrafenib plus trametinib, providing a much-needed treatment option for patients with treatment-resistant advanced disease.
Researchers at MD Anderson Cancer Center found that some commercially available serological tests only detect N-protein antibodies, which may not indicate immunity to reinfection. S-RBD antibody detection is considered a better indicator of protection against COVID-19 reinfection.
A Phase III trial led by the University of Texas MD Anderson Cancer Center found that combining venetoclax and azacitidine improved overall survival and achieved a 66.4% complete remission rate in patients with acute myeloid leukemia.
The study found that social distancing policies implemented in the US and globally led to significant reductions in SARS-CoV-2 transmission, with an estimated 1.57 million cases prevented over a two-week period. The researchers also observed a strong correlation between decreased mobility and reduced virus transmission.
A recent study by the University of Texas M. D. Anderson Cancer Center found that greater inactivity is independently associated with a higher risk of dying from cancer. Replacing sedentary time with physical activity, such as 30 minutes of cycling or walking, can lower this risk.
Researchers discovered a novel combination of biomarkers from baseline tumor tissues that predict improved clinical responses and prolonged survival in patients with advanced bladder cancer. ARID1A mutations and CXCL13 expression were associated with better overall survival, suggesting potential patient selection improvements.
A Phase II clinical trial has demonstrated a 46.5% objective response rate to tepotinib in patients with advanced non-small cell lung cancer and the MET exon 14 skipping mutation. The study's findings provide a new treatment option for this elderly population, with a durable response lasting almost one year.
A Phase Ib/II trial found that adding idh1 inhibitor ivosidenib to either venetoclax or azacitidine resulted in a high complete remission rate of 78% overall, with 100% for treatment-naïve patients. The combination may ultimately lead to a new therapeutic regimen and tailored treatment options based on molecular profiles.
A Phase II trial led by MD Anderson Cancer Center researchers found that treatment with MK-6482 resulted in a 27.9% objective response rate in patients with von Hippel-Lindau disease-associated renal cell carcinoma, with most side effects being grade 1 or 2. The drug directly targets HIF-2a and has been shown to be well-tolerated.
Researchers at MD Anderson Cancer Center and Ipsen Biopharmaceuticals have developed a novel drug, IPN60090, a glutaminase inhibitor for lung and ovarian cancers. The Phase I clinical trial shows promising results, particularly for patients with KEAP1/NRF2 mutations or low ASNS levels.
The Phase III EMBRACA trial found talazoparib improved patient-reported quality-of-life measures and had a tolerable safety profile in patients with metastatic HER2-negative breast cancer and BRCA1/2 mutations. However, the study did not demonstrate a statistically significant overall survival benefit due to subsequent treatments.
A Phase II trial found patients with metastatic castration-resistant prostate cancer who showed active T-cell responses in their tumors experienced prolonged survival after ipilimumab treatment. Researchers identified biomarkers associated with improved responses, including higher T-cell density and interferon-γ signaling.
A Phase II study found that 93% of patients with relapsed or refractory mantle cell lymphoma responded to CD19-targeting CAR T-cell therapy KTE-X19, with 67% achieving a complete response. The estimated progression-free survival and overall survival were 61% and 83%, respectively.
Researchers at MD Anderson Cancer Center propose using glucose transporter inhibitors to treat tumors with high expression of the SLC7A11 amino acid transporter. This approach targets cancer cells' dependency on glucose for survival, selectively killing 'addicted' cells.
Researchers at MD Anderson Cancer Center developed a combination therapy that reprograms effector T cells into persistent central memory T cells capable of self-renewal and effective cancer cell killing. This approach addresses the persistence challenge in cellular therapies, increasing their effectiveness.
A study found that myelin, the protective coating of nerve cells, is dynamic and not inert as traditionally believed. This discovery has implications for treatment of multiple sclerosis and chemobrain, a type of myelin damage caused by chemotherapy drugs.
A Phase II study found pembrolizumab to be effective in treating four rare cancer types with acceptable toxicity profiles. The treatment resulted in a median non-progression rate of 28% at 27 weeks, with complete response rates varying between 31-43% for each cancer type.
A study at MD Anderson Cancer Center found that using MLN4924 and dual treatment with anti-PD1 can induce durable, curative responses in patients with MMR-deficient and MSI cancers. The therapy approach shows promise as a novel therapeutic vulnerability for this type of cancer.
A new study has identified multiple factors contributing to osteosarcoma's poor responses to immunotherapy, including low immune cell infiltration and suppressed immune-stimulating neoantigens. The research provides insights into strategies for improving outcomes with immunotherapy in rare cancer types.
Researchers developed a novel method to analyze chemotherapy-resistant tumors using circulating tumor cells. Single-cell RNA sequencing revealed gene expression differences between individual cells, providing insight into the evolution of multiple resistance mechanisms.
Researchers found that oral cancers can reprogram nerves to grow into tumors, changing their function and fuelling growth. The team discovered that adrenergic nerves, involved in stress response, are susceptible to drugs used to treat high blood pressure and irregular heartbeats.
Researchers at the University of Texas MD Anderson Cancer Center have made significant progress in understanding the mitochondrial genome and its role in cancer. The study found that hyper-mutated cases in kidney, colorectal, and thyroid cancers suggest oncogenic impact with signaling pathway activation.
The CD19 CAR NK-cell therapy achieved a 73% response rate in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities reported. The treatment was administered in an outpatient setting, and responses were evident within one month following infusion.
A study published in Clinical Cancer Research found that circulating tumor cells were associated with a decrease in relapse-free survival at six months, and this association persisted at a 54-month longer-term follow-up. This suggests that CTC assessment may be useful in identifying patients at risk for relapse who could benefit from m...
A study by the University of Texas M. D. Anderson Cancer Center shows that a lung cancer screening decision aid delivered through tobacco quitlines effectively reaches a screening-eligible population and results in informed decisions about lung cancer screening. The decision aid, which explains eligibility, risks, and benefits, encoura...
Researchers found that B-cell markers were associated with improved overall survival in patients with advanced melanoma and soft-tissue sarcomas. B cells located within specialized immune-cell clusters (TLS) were predictive of response to checkpoint blockade, suggesting a dynamic interaction between immune components.
A study at University of Texas M.D. Anderson Cancer Center showed a potential new approach to treating follicular lymphoma and DLBCL through manipulation of molecular programs controlled by CREBBP. Inhibition of HDAC3 restores immune programs lost as a result of CREBBP mutations, paving the way for immunotherapy approaches.
A study by researchers at the University of Texas M.D. Anderson Cancer Center identified a subset of immune macrophages that resist treatment with anti-PD-1 checkpoint blockade in glioblastoma patients. The team found that these CD73-expressing macrophages were associated with decreased survival, and that targeting them with combinatio...
Researchers found that residual cancer burden index and classification are accurate and reliable tools to assess patient prognosis. The results suggest that continuous RCB index can predict risk of breast cancer recurrence across all four breast cancer subtypes.
The trial showed that adding tucatinib to capecitabine and trastuzumab improved progression-free and overall survival in advanced HER2-positive breast cancer patients, regardless of whether they had brain metastasis. The treatment combination also increased the overall response rate compared to standard care.
A one-year follow-up study of CAR T-cell therapy for relapsed mantle cell lymphoma found that 93% of patients responded to the treatment, with 67% achieving a complete response. The therapy was shown to be effective and viable option for patients with relapsed or refractory mantle cell lymphoma.
A new combination therapy of lower-dose chemotherapy and monoclonal antibodies has shown a 98% response rate in older patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia. The three-year survival rate was 54%, with 30 patients in complete remission without signs of minimal residual disease.
A Phase II study found that pairing standard chemotherapy azacitidine with the drug enasidenib significantly boosts complete remission in patients with acute myeloid leukemia (AML) and IDH2 mutations. The combination therapy was well-tolerated and showed improved overall response rates compared to chemotherapy alone.
A randomized trial found acupuncture significantly reduced radiation-induced dry mouth symptoms in head and neck cancer patients. The study, published in JAMA Network Open, suggests that incorporating acupuncture into radiation therapy may prevent severity of dry mouth symptoms, improving quality of life.
Researchers at UT MD Anderson Cancer Center found TBK1 and its adaptor protein contribute to tumorigenesis when activated by growth factors. Targeting TBK1 inhibits tumor growth and promotes antitumor immunity in mouse models.